Skip to main content
Pangen Biotech Inc. logo

Pangen Biotech Inc. — Investor Relations & Filings

Ticker · 222110 ISIN · KR7222110009 KO Manufacturing
Open in API
Filings indexed 333 across all filing types
Latest filing 2021-11-22 Major Shareholding Noti…
Country KR South Korea
Listing KO 222110

About Pangen Biotech Inc.

https://pangen.com/layout/eng/home.php

Pangen Biotech Inc. is a biotechnology company specializing in the research, development, and manufacturing of biopharmaceuticals. The company utilizes its proprietary platform technologies, particularly those based on Chinese Hamster Ovary (CHO) cell lines, for the production of complex protein therapeutics. Its primary business activities include the development of a pipeline of biosimilar products, such as Erythropoietin (EPO) and Aflibercept. In addition to its own product pipeline, Pangen Biotech offers Contract Development and Manufacturing Organization (CDMO) services, providing expertise in cell line development and biopharmaceutical production to other firms. The company also supplies reagents and kits for research applications.

Recent filings

Filing Released Lang Actions
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. This document type is used when a major shareholder (typically 5% or more) reports changes in their holdings or status. In the provided taxonomy, this corresponds to a 'Major Shareholding Notification'.
2021-11-22 Korean
[기재정정]최대주주변경을수반하는주식담보제공계약체결
Major Shareholding Notification Classification · 100% confidence The document is a regulatory filing from the Korea Exchange (KRX) system regarding a 'Pledge of Shares' (stock collateral contract) by a major shareholder. This type of filing, which details changes in collateral agreements, financing, and share ownership status, is classified under 'Regulatory Filings' (RNS) as it serves as a formal disclosure of corporate events that do not fit into specific categories like M&A, dividends, or earnings releases.
2021-11-22 Korean
기업설명회(IR)개최
Report Publication Announcement Classification · 100% confidence The document is a short announcement (under 1,000 characters) regarding the scheduling and logistics of an upcoming Investor Relations (IR) event. It provides the date, time, location (online), and purpose of the meeting, and mentions that materials will be distributed on the day of the event. Since it is an announcement of an event rather than the presentation itself, and it serves as a regulatory notification of corporate activity, it fits the criteria for a Report Publication Announcement or general regulatory filing. Given the specific nature of announcing an IR event, it is classified as an RPA.
2021-11-18 Korean
분기보고서 (2021.09)
Interim / Quarterly Report Classification · 100% confidence The document is a '분기보고서' (Quarterly Report) for the company 'PanGen' (팬젠) covering the period from 2021.01.01 to 2021.09.30. It contains detailed financial data, business operations, management discussions, and capital structure information. It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). 9M 2021
2021-11-12 Korean
[기재정정]주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on Granting of Stock Options) and specifically a '정정신고' (Amendment Report). It details changes to the number of stock options granted to employees and executives due to resignations. This type of disclosure regarding share-based compensation and capital structure changes falls under the category of share issues or capital changes in the context of regulatory filings.
2021-09-30 Korean
투자판단관련주요경영사항(A형 혈우병 치료제 PGA40의 다국가 임상3상시험 계획변경 승인)
Regulatory Filings Classification · 95% confidence The document is a regulatory filing from the Korean Exchange (KRX) system, specifically a 'Major Management Matter' (투자판단 관련 주요경영사항) disclosure. It details the approval of a clinical trial plan change for a drug (PGA40) by the Ministry of Food and Drug Safety. Since this is a formal regulatory disclosure of a material corporate event that does not fit into specific categories like financial reports or shareholder meetings, it falls under the 'Regulatory Filings' category.
2021-09-17 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.